About Cerenome / Our Team

The expertise behind the platform.

Cerenome is approaching central nervous system (CNS) cancer as a solvable system rather than a series of disconnected challenges. That takes a particular kind of team: scientists, clinicians, and leadership who chose depth over breadth, and who came to work on one of medicine’s hardest problems on purpose.

Leadership

The people leading our work.

  • Marc Hedrick, MD, MBA

    President and CEO

    Dr. Marc Hedrick was previously President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. He is a trained general, vascular, and plastic surgeon and formerly served as Associate Professor of Surgery and Pediatrics and as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.

    Dr. Hedrick holds an MD from the University of Texas Southwestern Medical School and an MBA from the UCLA Anderson School of Management.

  • Andrew Sims, CPA

    VP and Chief Financial Officer

    Andrew Sims previously served as CFO of several private equity-backed companies, with a focus on M&As, integrations, corporate capitalization, and developing teams to support global growth.

    He was a Partner at Mazars, where he audited and advised global public companies, including healthcare organizations with average annual revenues exceeding $1 billion.

    Sims is a CPA in the U.S. and a CA in England and Wales. He holds a degree in Accounting and Financial Management from Buckingham University.

  • Eric J. Daniels, MD, MBA

    Chief Development Officer

    Dr. Eric Daniels has over 20 years of experience across clinical development, regulatory strategy, operations, and business development.

    Previously, he was Chief Development Officer of Kiora Pharmaceuticals, Executive Director and Co-Founder of Bayon Therapeutics, and Co-Founder and Director of Okogen.

    Dr. Daniels holds an MD from the University of California, Los Angeles School of Medicine, an MBA from the UCLA Anderson School of Management, and a BS from the University of California, Berkeley.

  • Russ Havranek, MS, MBA

    EVP, Commercial and Corporate Strategy

    Russ Havranek has 30 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded biopharmaceutical and medical device companies. Previously, he held roles at Cytori Therapeutics, Johnson & Johnson, Guidant (Abbott), and Genentech (Roche), among others.

    Havranek holds an MBA from the Haas School of Business, an MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.

  • Russell Bradley

    President and General Manager, CNSide Diagnostics

    Russell Bradley is a senior executive in the life science and clinical diagnostics markets, having led the evaluation, market assessment, and commercial launch of multiple clinical diagnostics and life science technologies. Previously, he was a General Manager, leading the Hematology Business Unit at Abbott Laboratories. He also held senior roles at Luminex, Inc. and spent 17 years at Beckman Coulter.

    Bradley holds a B.Sc. in Immunology and Biochemistry from Monash University.

  • Daniel Ortega, MBA

    VP, Development and Technical Operations

    Daniel Ortega is responsible for end-to-end drug development, GMP manufacturing, clinical supply chain management, and CMC oversight across the company’s radiotherapeutic portfolio.

    Ortega brings nearly 20 years of pharmaceutical industry experience, including technical and leadership roles at Azaya Therapeutics, Mission Pharmacal, and Viatris, formerly DPT Laboratories.

    Ortega holds an MBA from Texas A&M University-San Antonio and BS degree from the University of Texas at San Antonio.

  • Randy H. Goodman, PhD, MHA

    VP, Value Strategy and HEOR

    Dr. Randy H. Goodman has over 20 years of experience across global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling.

    He previously advised Pfizer, Gilead Sciences, and Moderna; worked with the Centers for Medicare & Medicaid Services; and been a healthcare policy advisor to the White House.

    Dr. Goodman holds a PhD and MHA from the Harvard T.H. Chan School of Public Health and a BA in Medical Communications from North Texas State University.

  • Colby Suire, PhD

    VP, Research and Development

    Dr. Colby Suire leads scientific strategy and execution for CNSide and its translational and diagnostic capabilities.

    He has over 18 years of experience in translational science and drug development and previously served as CEO and Head of Development at K2 Biolabs and held senior roles at Talaris Therapeutics and Neurogene.

    Dr. Suire holds a PhD in Biomedical Science from The University of Texas Health Science Center at Houston and a BS in Biological Sciences from Louisiana State University.

  • Samantha Fowlkes

    VP, Head of Commercial Sales, CNSide Diagnostics

    Samantha Fowlkes leads the commercial expansion of sales and operations for the Company’s neuro-oncology portfolio.

    She previously held leadership roles at Caris Life Sciences and worked in precision medicine, account implementation, and clinical operations. Fowlkes has 20 years of experience in advancing healthcare innovation, building collaborations, and helping teams address oncology needs. She is a certified CSSC-G and holds BS degrees in Biology and Psychology from Texas Women’s University.

  • Michelle Purdom, PhD, RN

    VP, Clinical Operations

    Dr. Michelle Purdom, PhD, RN, has over 25 years of experience in oncology, spanning clinical research, clinical operations, medical affairs, and biotech leadership.

    Previously, she was a clinical consultant at SSI Strategy and held roles at Mythic Therapeutics and TG Therapeutics.

    Dr. Purdom holds a PhD in Nursing Education from the University of Texas at Tyler, an MSN in Leadership in Healthcare Organizations from The University of Texas Medical Branch, and a BSN from Pace University.

  • Kara Q. Davis

    VP, Legal Affairs

    Kara Quinlan Davis leads the legal function for Cerenome and CNSide Diagnostics. She brings approximately 25 years of legal experience spanning in-house corporate counsel roles and private practice at leading law firms.

    Previously, Davis was Of Counsel at Nelson Mullins Riley & Scarborough and an attorney at Baker Donelson. She also spent seven years as Counsel at INVESCO.

    Davis holds a JD from Vanderbilt University Law School and a BA in Government from the University of Virginia.

  • Chris Murray

    VP, Human Resources

    Chris Murray is a human resources executive with 25 years of experience leading people strategy for public, private, start-up, and pre-IPO companies.

    Previously, he was Interim Senior Director of Human Resources at IES Residential. Earlier, Murray held roles at Sysco, Triumvira Immunologics, and Bellicum Pharmaceuticals.

    Murray is the founder of Vivid HR Consulting, a Certified Change Management Professional, and holds a BA in Business Management from American InterContinental University.

Board of Directors

Guiding our trajectory.

  • Richard Hawkins

    Chairman

    Richard Hawkins is currently CEO of Lumos Pharma, Inc.

    Previously, he founded LabNow Inc., a diagnostic device company developing rapid, point-of-care diagnostic testing systems, and served as Chairman and CEO. He also founded and led Pharmaco and founded id2 and Sensus Drug Development Corp. He also served as Chairman of the Board of LoopOne, Inc., a shipping and logistics software company.

    Hawkins holds a BS in Biology from Ohio University.

  • Ron Andrews

    Director

    Ron Andrews is a diagnostics and molecular diagnostics industry leader with over 35 years of experience. He has led organizations ranging from divisions of global companies, including Abbott Diagnostics, Roche Molecular Diagnostics, and Life Technologies/Thermo Fisher, to public biotechnology and diagnostics companies, including Clarient Inc. and Oncocyte Inc.

    Andrews serves on the Board of Trustees for Wofford College and holds BS degrees in Biology and Chemistry from Wofford College.

  • Howard Clowes

    Director

    Howard Clowes is a retired partner after nearly four decades at DLA Piper. He held leadership positions in the firm’s corporate and securities practice, advising public and private companies on securities law, financing, M&As, and general corporate matters.

    Clowes also serves as a Lecturer at the University of California, Berkeley. He holds a JD from the University of California, Berkeley, and a BA from the University of California, Santa Barbara.

  • An van Es-Johansson, MD

    Director

    Dr. An van Es-Johansson is a Senior Advisor for AlzeCure Pharma, a pharmaceutical company focused on Alzheimer’s disease, where she is responsible for regulatory affairs, clinical development, clinical operations, and pharmacovigilance.

    Previously, she held roles at Swedish Orphan Biovitrum AB, Roche, and Eli Lilly.

    Dr. van Es-Johansson currently serves on the boards of Lumos Pharma, Medivir AB, Agendia Inc., and Savara Inc. She holds an MD from Erasmus University.

  • Kyle Guse

    Director

    Kyle Guse has 30 years of professional experience across biotechnology, corporate law, finance, and public company leadership. Previously, she served as CFO, General Counsel, and Secretary of Atossa Therapeutics, Inc.

    Earlier, Guse was a partner practicing corporate law at several international law firms.

    Guse holds a JD from Santa Clara University School of Law, an MBA from California State University, Sacramento, and a BS from California State University, Sacramento.

Come build it with us.

Work on one of oncology’s hardest problems, with a team committed to nothing else.